MedRhythms, in collaboration with Boston University, is launching a clinical trial of its pipeline asset MR-005 in Parkinson’s disease (PD).
In addition, the company is expanding its pipeline into aging with the development of its Aging Scientific Advisory Board (SAB). This follows MedRhythms’ announcement of the advancement of its pipeline into PD and multiple sclerosis (MS) in 2020 with the initiation of clinical trials and the development of MS and PD SABs.
MedRhythms, headquartered in Portland, Me, is a digital therapeutics company that builds direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury.
Exploring Efficacy of Home Use
The multi-site clinical trial studying MR-005, a digital therapeutic for PD walking impairments, will evaluate the clinical efficacy of the asset when deployed remotely in the home setting.
The study will be led by Dr. Terry Ellis, Chair of the Department of Physical Therapy & Athletic Training at Boston University College of Health & Rehabilitation Sciences: Sargent College, Director of Boston University’s Center for Neurorehabilitation, and Director of Boston University’s Neurologic Physical Therapy Residency Program, in collaboration with a Co-P.I. and neurologist at the leading hospital, a media release from MedRhythms explains.
“This product has enormous potential to help people living with Parkinson’s disease. People with Parkinson’s need more options for interventions to improve walking ability. Music, particularly Rhythmic Auditory Stimulation, is a promising intervention for individuals with Parkinson’s disease, as has been shown through decades of evidence in its ability to improve gait and reduce falls in this population. MR-005 provides an opportunity for this intervention to be delivered at scale, and we are excited to be a part of its development.”
— Dr. Terry Ellis
This study follows MedRhythms’ previous clinical trials in chronic stroke and MS. The chronic stroke study is an 8-center randomized controlled trial and the Company’s pivotal trial for this asset. The MS trial is a feasibility study at Cleveland Clinic. Each study follows MedRhythms’ commitment to building strong clinical evidence for its digital therapeutics, the release continues.
Aging Scientific Advisory Board
MedRhythms welcomes Joe Verghese, MD, MS, Kirk Erickson, PhD, and Alvaro Pascual-Leone, MD, PhD, to the Company’s inaugural Aging Scientific Advisory Board.
Verghese is the Director of The Saul R. Korey Department of Neurology Division of Cognitive & Motor Aging and the Director at the Jack and Pearl Resnick Gerontology Center at Albert Einstein School of Medicine. Erickson is a Professor and the Director and Principal Investigator of the Brain Aging & Cognitive Health Lab at the University of Pittsburgh and Center for the Neural Basis of Cognition. Pascual-Leone is the Medical Director of the Deanna and Sidney Wolk Center for Memory Health, a Senior Scientist at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, and a Professor of Neurology at Harvard Medical School.
“I look forward to supporting MedRhythms through the development and rigorous testing of their asset in aging. This digital therapeutic has the potential to make a significant impact in the aging population.”
— Joe Verghese
“As we expand our pipeline into new populations, we are honored to be collaborating with some of the world’s leading minds to accomplish our mission and provide important care where there are high unmet needs.”
— Brian Harris, the CEO and co-founder of MedRhythms
[Source(s): MedRhythms, PR Newswire]
Related Content:
MedRhythms Advances Pipeline of Products in MS and Parkinson’s
Trial Launched to Test MedRhythms’ Post-Stroke Walking Device
MedRhythms Aims to Help Stroke Patients Add Rhythm to Their Steps
